← All trials
NCT04870021
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2015
- Primary completion
- Nov 30, 2015
- Completion date
- Jun 30, 2016
- First posted
- May 3, 2021
- Last posted
- May 3, 2021
- Enrollment
- 218
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Quaid-i-Azam University (QAU)Lead sponsor
- Government of PakistanCollaborator
- Quaid-i-Azam University (QAU)Reponsible party - principal investigator
- Health Services Academy, Islamabad, PakistanOverall official - principal investigator
- Health Services Academy, Islamabad, PakistanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.